Tazemetostat

COMPOSITION:

Each film-coated tablet contains Tazemetostat hydrobromide 228 mg equivalent to Tazemetostat……………………………200mg.

INDICATION:

LuciTaze is a methyltransferase inhibitor indicated for the treatment of:

• Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

• Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation test and who have received at least 2 prior systemic therapies.

• Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

DOSAGE AND USE:

• Recommended dosage is 800 mg taken orally twice daily with or without food.

• Swallow tablets whole. Do not cut, crush, or chew tablets.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciTaze during Pregnancy and Lactation.